AstraZeneca (NASDAQ:AZN) shares gained in European trading on Thursday after the Anglo-Swedish drugmaker reported better-than-expected Q4 2024 results and addressed investor concerns over an ...
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...
AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback